This Special Issue focuses on the efficacy and safety of current treatment strategies for patients with connective tissue disease-related interstitial lung disease, including the use of immunosuppressants, such as cyclophosphamide, mycophenolate mofetil, rituximab and antifibrotic drugs.
Editorial
This Editorial introduces the Special Issue on the efficacy and safety of current treatment strategies for patients with connective tissue disease-related interstitial lung disease, including the use of immunosuppressants, such as cyclophosphamide, mycophenolate mofetil and rituximab, and antifibrotic drugs.
Review
This review focuses on cyclophosphamide due to its crucial role in the treatment of systemic sclerosis-related interstitial lung disease, particularly in the case of patients with progressive Interstitial lung diseases.
Review
This review describes the available data and recent advances on the effectiveness and safety of MMF for the treatment of ILD related to RD, including rheumatoid arthritis, systemic sclerosis, primary Sjögren syndrome, systemic lupus erythematosus, idiopathic inflammatory myopathies, undifferentiated connective tissue disease, interstitial pneumonia with autoimmune features and antineutrophil cytoplasmic antibody-associated vasculitis.
Review
This article reviews the available efficacy and safety data on the use of rituximab in the treatment of rheumatic disease-related interstitial lung disease.
Review
This review discusses the experimental evidence and clinical trials investigating the efficacy and safety of antifibrotic drugs in patients with CTD-ILDs and the potential mechanisms of action involved.
